141 related articles for article (PubMed ID: 11739902)
1. Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies.
Völkel T; Korn T; Bach M; Müller R; Kontermann RE
Protein Eng; 2001 Oct; 14(10):815-23. PubMed ID: 11739902
[TBL] [Abstract][Full Text] [Related]
2. Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region.
Alt M; Müller R; Kontermann RE
FEBS Lett; 1999 Jul; 454(1-2):90-4. PubMed ID: 10413102
[TBL] [Abstract][Full Text] [Related]
3. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives.
Stork R; Campigna E; Robert B; Müller D; Kontermann RE
J Biol Chem; 2009 Sep; 284(38):25612-9. PubMed ID: 19628871
[TBL] [Abstract][Full Text] [Related]
4. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin.
Müller D; Karle A; Meissburger B; Höfig I; Stork R; Kontermann RE
J Biol Chem; 2007 Apr; 282(17):12650-60. PubMed ID: 17347147
[TBL] [Abstract][Full Text] [Related]
5. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
6. Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody.
Le Gall F; Reusch U; Little M; Kipriyanov SM
Protein Eng Des Sel; 2004 Apr; 17(4):357-66. PubMed ID: 15126676
[TBL] [Abstract][Full Text] [Related]
7. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I
Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485
[TBL] [Abstract][Full Text] [Related]
8. N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies.
Stork R; Zettlitz KA; Müller D; Rether M; Hanisch FG; Kontermann RE
J Biol Chem; 2008 Mar; 283(12):7804-12. PubMed ID: 18211902
[TBL] [Abstract][Full Text] [Related]
9. Cloning, expression, purification and characterization of a bispecific single-chain diabody against fluoroquinolones and sulfonamides in Escherichia coli.
Chen M; Wen K; Tao X; Xie J; Wang L; Li Y; Ding S; Jiang H
Protein Expr Purif; 2014 Aug; 100():19-25. PubMed ID: 24816423
[TBL] [Abstract][Full Text] [Related]
10. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module.
Stamova S; Cartellieri M; Feldmann A; Arndt C; Koristka S; Bartsch H; Bippes CC; Wehner R; Schmitz M; von Bonin M; Bornhäuser M; Ehninger G; Bachmann M
Mol Immunol; 2011 Dec; 49(3):474-82. PubMed ID: 22014687
[TBL] [Abstract][Full Text] [Related]
11. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein.
Hopp J; Hornig N; Zettlitz KA; Schwarz A; Fuss N; Müller D; Kontermann RE
Protein Eng Des Sel; 2010 Nov; 23(11):827-34. PubMed ID: 20817756
[TBL] [Abstract][Full Text] [Related]
12. Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv.
Korn T; Nettelbeck DM; Völkel T; Müller R; Kontermann RE
J Gene Med; 2004 Jun; 6(6):642-51. PubMed ID: 15170735
[TBL] [Abstract][Full Text] [Related]
13. Intracellular and cell surface displayed single-chain diabodies.
Kontermann RE; Müller R
J Immunol Methods; 1999 Jun; 226(1-2):179-88. PubMed ID: 10410983
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody.
Asano R; Ikoma K; Shimomura I; Taki S; Nakanishi T; Umetsu M; Kumagai I
J Biol Chem; 2011 Jan; 286(3):1812-8. PubMed ID: 21097496
[TBL] [Abstract][Full Text] [Related]
15. The role of valency in the selection of anti-carbohydrate single-chain Fvs from phage display libraries.
MacKenzie R; To R
J Immunol Methods; 1998 Nov; 220(1-2):39-49. PubMed ID: 9839924
[TBL] [Abstract][Full Text] [Related]
16. The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility.
Carmichael JA; Power BE; Garrett TP; Yazaki PJ; Shively JE; Raubischek AA; Wu AM; Hudson PJ
J Mol Biol; 2003 Feb; 326(2):341-51. PubMed ID: 12559905
[TBL] [Abstract][Full Text] [Related]
17. Effects of different interchain linkers on biological activity of an anti-prostate cancer single-chain bispecific antibody.
Hao CH; Han QH; Shan ZJ; Hu JT; Zhang N; Zhang XP
Theor Biol Med Model; 2015 Aug; 12():14. PubMed ID: 26246000
[TBL] [Abstract][Full Text] [Related]
18. [Construction and expression of an anti-EGFR/anti-KDR bispecific single-chain diabody].
Zhou YQ; Zhang J; Jin HZ; He Y; Wang T; Wang M
Yao Xue Xue Bao; 2012 Oct; 47(10):1317-22. PubMed ID: 23289143
[TBL] [Abstract][Full Text] [Related]
19. Structural diversity and flexibility of diabodies.
Kwon NY; Kim Y; Lee JO
Methods; 2019 Feb; 154():136-142. PubMed ID: 30261312
[TBL] [Abstract][Full Text] [Related]
20. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
